We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In a letter to 17 major drugmakers, the Interfaith Center on Corporate Responsibility — an association whose members include faith communities, asset managers, unions, pensions and investor groups — called on the companies to set affordable prices for COVID-19 vaccines and treatments, and to share technology to scale up manufacturing to ensure widespread access to their products. Read More
Peer-reviewed preliminary data from Pfizer’s and BioNTech’s U.S. phase 1/2 trial of its COVID-19 vaccine candidate BNT162b1 were released yesterday, confirming findings previously released by the companies in early July. Read More
Mexico’s drug regulators have approved RedHill Biopharma’s planned phase 2/3 trial of Yeliva (opaganib) in hospitalized COVID-19 patients with pneumonia. Read More
Vir Biotechnology plans to launch a phase 2/3 trial this month of VIR-7831, a neutralizing monoclonal antibody for the treatment of COVID-19 patients. Read More
Moderna has secured a $1.5 billion Operation Warp Speed contract to supply 100 million doses of a COVID-19 vaccine candidate to the U.S. government, with an option to supply 400 million more doses if needed. Read More
Mexico has agreed to host several phase 3 clinical trials of potential COVID-19 vaccines as the pace of research worldwide continues to gain momentum. Read More
Novavax plans to have enough COVID-19 vaccine manufacturing capacity to meet U.S. demand at a minimum, but the Maryland-based vaccine developer is also looking to be able to supply billions of doses next year, the company’s CEO said. Read More
Moderna said that it might not be the first company to make the inventions claimed on patent applications for its COVID-19 vaccine mRNA-1273, and that the company may have to seek patent licenses to market the vaccine. Read More
Russia has approved the world’s first coronavirus vaccine, President Vladimir Putin announced Tuesday, prompting widespread concerns about the vaccine’s safety as it is only entering a late-stage clinical trial this week. Read More